Evidence map›Paper›PMID 35817479›Full record

ArticleJournal for immunotherapy of cancer2022

Gallic acid induces T-helper-1-like T

Biaolong Deng, Biaolong Yang, Jieqiong Chen, Shuaiwei Wang, Weiqi Zhang, Yixian Guo, Yichao Han, Hecheng Li, Yongjun Dang, Yaqin Yuan and 4 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Nobiletin in the modified Yiqi Jianpi Decoction enhances the antitumor activity of CD8The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  3. Article
  4. Analysis of Quality Differences inFood science & nutrition · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Advanced RPL19-TRAPNatural products and bioprospecting · 2025
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Biaolong Deng *Center for Immune-Related Diseases at Shanghai Institute of Immunology, Department of Respiratory and Critical Care Medicine of Ruijin Hospital, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Biaolong Yang *Department of Medical Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Jieqiong ChenShanghai Affinity Biopharmaceutical Co., Ltd, Shanghai, China.
Shuaiwei WangCenter for Immune-Related Diseases at Shanghai Institute of Immunology, Department of Respiratory and Critical Care Medicine of Ruijin Hospital, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weiqi ZhangCenter for Immune-Related Diseases at Shanghai Institute of Immunology, Department of Respiratory and Critical Care Medicine of Ruijin Hospital, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yixian GuoShanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.ORCID 0000-0002-4542-4929
Yichao HanDepartment of Thoracic Surgery, RuiJin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hecheng LiDepartment of Thoracic Surgery, RuiJin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yongjun DangFudan University School of Basic Medical Sciences, Shanghai, China.
Yaqin YuanCenter for Immune-Related Diseases at Shanghai Institute of Immunology, Department of Respiratory and Critical Care Medicine of Ruijin Hospital, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xueyu DaiCenter for Immune-Related Diseases at Shanghai Institute of Immunology, Department of Respiratory and Critical Care Medicine of Ruijin Hospital, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuansheng ZangDepartment of Medical Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Yangyang LiUnit of Immune and Metabolic Regulation, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.ORCID 0000-0002-5791-9443
Bin LiCenter for Immune-Related Diseases at Shanghai Institute of Immunology, Department of Respiratory and Critical Care Medicine of Ruijin Hospital, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China binli@shsmu.edu.cn.
Shanghai Jiao Tong University · CNShanghai Changzheng Hospital · CNAffinity Water (United Kingdom) · GBFudan University · CNShanghaiTech University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFoxp3

methodsWe have screened 2640 compounds and identified the gut microbial metabolite gallic acid, which promotes Foxp3 degradation and T

resultsMechanistically, gallic acid prevents STAT3 phosphorylation and the binding of phosphorylated STAT3 to

conclusionOur findings have implications for improving the efficacy of ICB therapy in CRC by inducing T-helper-1-like Foxp3

Indexed as

B7-H1 AntigenNeoplasmsAnimalsCD8-Positive T-LymphocytesForkhead Transcription FactorsGallic AcidImmune Checkpoint InhibitorsMiceTumor MicroenvironmentB7-H1 AntigenForkhead Transcription FactorsGallic AcidImmune Checkpoint InhibitorsimmunotherapyT-Lymphocytestumor microenvironment

Identifiers

PMID35817479
PMCPMC9274539
OpenAlexW4285007989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.